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Abstract
Background: Fifteen million adults in the World Health Organization European Region are estimated to have
active hepatitis C infection. Intravenous drug use is a major hepatitis C transmission route in this region, and
people who inject drugs (PWID) constitute a high-risk and high-prevalence population. A systematic review was
conducted to assess levels of hepatitis C treatment uptake among PWID in Europe.
Methods: Searches in MEDLINE and EMBASE were carried out for articles in any language published between
1 January 2000 and 31 December 2012. Articles were included in the review if they presented original research
findings about hepatitis C treatment uptake levels among people who reported injecting drugs currently or
formerly, as well as those who reported using drugs currently or formerly (mode of consumption not specified).
Treatment uptake data were extracted if uptake was measurable in relation to the number of patients who either:
(a) tested HCV antibody-positive; (b) tested positive for HCV-RNA; or (c) tested positive for HCV-RNA and met
additional treatment criteria.
Results: Twenty-five articles from 12 countries were included in the review. Among groups of drug-using study
participants who were hepatitis C antibody-positive, the median treatment uptake level was 17%, and among
those who were hepatitis C RNA-positive, the median was 30%. In the 11 studies reporting specifically on
treatment uptake among current and former injecting drug users, hepatitis C RNA-positive study populations had a
median treatment uptake level of 32%. Only one study reported on treatment uptake for current drug users.
Conclusions: This systematic review indicates that hepatitis C treatment uptake is relatively low among drug users
in several European countries, and also points to considerable knowledge gaps regarding treatment uptake levels
in this population. There was large variability in treatment uptake levels, suggesting that there may be major
differences between and within countries in relation to treatment availability, drug-using populations in need of
treatment, and the existence of integrated health care services targeting drug users. Stronger national hepatitis C
treatment policies are needed, along with efforts to increase knowledge and reduce misconceptions among
physicians regarding the feasibility and importance of treating drug users who have hepatitis C.
Introduction
An estimated 185 million people worldwide have
acquired the hepatitis C virus (HCV) [1], many of them
without being aware of their infection. Chronic disease
can be expected to occur in 55% to 85% of untreated
cases, and potential long-term outcomes for chronically
infected people include liver cirrhosis, liver failure and
hepatocellular carcinoma [2]. A 2006 assessment of the
global burden of disease from hepatitis B and hepatitis C
put annual HCV-related mortality at 366,000 [3], while
more recent research yielded an estimate of 499,000
deaths due to HCV in 2010 [4].
In the World Health Organization (WHO) European
Region, 15 million adults are estimated to have active
HCV infection as defined by the presence of HCV-RNA.
This translates into a regional adult prevalence rate of
2.0% [5]. While the limitations of the available data
invite some uncertainty about the magnitude of the
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HCV epidemic in the region overall, numerous studies
provide evidence of high HCV antibody levels (indicat-
ing either current or previous infection) in specific
countries and subnational regions. For example, a 2013
review article identified reports of HCV antibody preva-
lence levels in the general population ranging from 0.1%
to 22% at the national and subnational level in 13 Eur-
opean countries. The article observed that prevalence
was lower in northwestern European countries and
higher in the countries of the south and southeast [6].
Injecting drug use is a major driver of the HCV epidemic
in Europe. According to the 2013 European Drug Report:
Trends and Developments, injecting drug use accounted for
58% of all HCV diagnoses across 18 European countries for
which 2010/2011 data were available [7]. An analysis of
HCV-RNA prevalence data from the WHO European
Region concluded that two million of the region’s 15 million
adults with HCV-RNA are people who inject drugs (PWID)
[5]. While wide-ranging HCV antibody prevalence levels
have been found across different PWID cohorts, overall pre-
valence in this population appears to be much higher than
in the general population. According to a 2013 systematic
review, HCV antibody prevalence among PWID in 29
European countries ranged from 5% to 90% [6]. The 2013
European Drug Report noted that in eight of 12 countries
with HCV antibody data from national samples of PWID,
prevalence exceeded 40% [7].
Effective and safe HCV treatment can be used in the
majority of infected patients and would greatly reduce the
associated morbidity and mortality. Several studies have
shown that HCV treatment outcomes in PWID are com-
parable to those in patients with no history of drug use
[8,9]. Additionally, treatment also helps to prevent trans-
mission by eliminating the potential source of infection
[10]. Nevertheless, current treatment uptake overall is low,
and treatment rates appear to be lowest among the most
affected at-risk group: PWID [11]. Barriers to HCV treat-
ment are most likely to be present on different levels
including the patient, provider and system levels [11].
These barriers may include a lack of knowledge, a lack of
financial resources and a fear of side-effects among patients,
as well as concerns of adherence and the risk of re-infection
at the provider level [11]. Another barrier is the setting
itself, which needs to be suitable for this group and able to
adequately handle different needs in this vulnerable popula-
tion [12] as well as address associated stigma [13].
The purpose of this article is to systematically review
the evidence on hepatitis C virus treatment uptake
among PWID in the WHO European Region.
Methods
We performed a systematic review of literature on HCV
treatment uptake among PWID in the WHO European
Region (Figure 1). Searches were carried out in MEDLINE
and EMBASE for articles in any language published
between 1 January 2000 and 31 December 2012. A sensi-
tive search string (available upon request) was developed
with keywords covering hepatitis C virus, substance abuse,
geographic scope and access to treatment. Additional arti-
cles, including grey literature articles, were located
through e-mail consultations with a network of experts
representing 27 European Union countries. The protocol
was made consistent with the PRISMA criteria as
described elsewhere [14,15]. This study draws upon the
protocol of a similar systematic review on treatment
uptake among PWID [15], but important differences in
inclusion and exclusion criteria and reporting of the
results explains the differences in the findings.
Two researchers independently screened search results
for relevance on the basis of titles and abstracts, then
compared their findings. When there was uncertainty
about the relevance of an item, it was retained for further
consideration. Next, two researchers independently eval-
uated all potentially relevant articles on the basis of the
full article text using predetermined inclusion and exclu-
sion criteria (Box 1). Additional articles were identified
and screened by examining the reference lists of articles
found to be eligible for inclusion. The final set of articles
underwent data extraction. Native speakers provided
assistance with screening and data extraction for non-
English articles, and online translation services (Google
Translate and BabelFish) were utilised as well.
Box 1. Inclusion and exclusion criteria for articles
Inclusion criteria
• Original research findings about treatment uptake
levels in HCV patient cohorts (not articles reporting
on modelling findings or systematic reviews).
• Study participants who reported injecting drugs
currently or formerly as well as those who reported
using drugs currently or formerly (mode of consump-
tion not specified).
• Treatment uptake level measurable in relation to
the number of patients who either: (a) tested HCV
antibody-positive; (b) tested positive for HCV-RNA;
or (c) tested positive for HCV-RNA and met addi-
tional treatment criteria.
• Data collected after 1990.
• Unselected study population.
Exclusion criteria
• Study cohort comprised solely of people who
reported non-injecting drug use.
• Study findings based on modelling rather than
actual patient data.
• Use of hepatitis C treatment determined by
patient self-report.
• Confusing, ambiguous or self-contradictory
study findings.
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The following primary and secondary outcomes of interest
guided data extraction. The primary outcome of interest
was the proportion of drug users initiating HCV treatment
from among all drug users who were candidates for HCV
treatment; this was regarded as the treatment uptake level.
Drug users generally rather than PWID were deemed the
population of interest because it was noted that few
studies appeared to clearly differentiate among these
two populations when reporting treatment uptake levels.
We defined candidates for HCV treatment as those
patients who either: (a) tested HCV antibody-positive;
(b) tested positive for HCV-RNA; or (c) tested positive for
HCV-RNA and met additional treatment criteria specified
in the study protocol. Secondary outcomes of interest
were treatment uptake levels for specific types of patient
cohorts (e.g., current drug users); levels of sustained viral
response (SVR) in treated cohorts; and findings about the
age and sex of patients obtaining treatment.
Results
Studies included in review
Table 1 provides characteristics of the 25 studies included
in the review. The studies were carried out in 12 countries.



















1 Only in the 28 members states of the European Union and not the entire European Region (n=53). 
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Figure 1 Flow diagram of study selection
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Table 1 Characteristics of included studies
Author, year Country Study design Study population
Study setting: drug treatment clinic
Backmund et al, 2001 Germany Prospective
cohort study
100 drug users who were diagnosed HCV-RNA positive while receiving inpatient
detoxification treatment. HCV treatment exclusion criteria included severe depression
and HIV-positive diagnosis.
Ebner et al, 2009 Austria Randomised
controlled study
75 HCV-RNA positive drug users diagnosed with opioid dependence and receiving
addiction treatment services. Patients were not eligible for HCV treatment unless they






225 drug users found to be HCV antibody-positive while they were receiving services at
an addiction outpatient unit. Patients were further screened for treatment eligibility via
HCV-RNA testing and liver biopsy.
Guadagnino et al, 2007 Italy Prospective
cohort study
169 HCV-RNA positive PWID identified at 11 drug dependency units. These patients
were referred to collaborating infectious diseases clinical centres for evaluation
regarding their suitability for HCV treatment, then the drug dependency units
supervised treatment.
McCormick et al, 2008 Ireland Prospective
cohort study
13 drug treatment clinic patients who were diagnosed HCV-RNA positive and met
study inclusion criteria. These included being stable on methadone; having a six-month
record of abstinence from intravenous drug use; and having HCV genotype 2 or 3.
Moussalli et al, 2010 France Cross-sectional
study
337 patients at a drug users’ addiction centre: 113 diagnosed HCV-RNA positive before
an HCV intervention was introduced, and 224 diagnosed HCV-RNA positive after the
introduction of the intervention, which included an on-site multidisciplinary health care
team.
Schulte et al, 2010 Germany Prospective
cohort study
301 HCV antibody-positive people receiving heroin maintenance at five drug treatment
centres. The hepatitis C treatment study was nested within a heroin maintenance study.




Patient files examined for 115 HCV-RNA positive PWID at a drug treatment clinic.




441 HCV-RNA positive drug users identified by offering HCV testing to all patients at a
drug treatment clinic and referringtreatment candidates to a monthly hepatology
outreach clinic within the drug treatment unit.
Witteck et al, 2011 Switzerland Cross-sectional
study
193 HCV-RNA positive patients identified in opioid substitution programmes in two
Swiss cities.
Study setting: hepatitis clinic
Cournot et al, 2004 France Retrospective
cohort study
Data for 225 HCV antibody-positive PWID including 41 current PWID analysed as part of
a study of a larger cohort of 435 people attending inpatient and outpatient clinics at a
hospital hepato-gastroenterology unit.
Crespo et al, 2001 Spain Prospective
cohort study
416 HCV antibody-positive PWID were among 1269 people referred for therapeutic
evaluation at a university hospital-based hepatitis clinic.
Gazdag et al, 2010 Hungary Retrospective
cohort study
83 HCV-RNA positive PWID at a hepatology outpatient clinic.




253 HCV antibody-positive patients who attended a regional (referral) liver unit and
who had reported injecting drug use as their main risk factor for HCV.
Kieran et al, 2011 Ireland Retrospective
cohort study
Subset of 327 HCV-RNA positive people reporting injecting drug use as their HCV risk
factor at a clinic for the integrated management of HIV and HCV.
Study setting: other/unknown
Broers et al, 2005 Switzerland Prospective
cohort study
22 PWID included in a cohort of 27 patients offered treatment upon being diagnosed
with acute or subacute hepatitis C.
Cullen et al, 2007 Ireland Retrospective
cohort study
104 HCV antibody-positive drug users who were among a cohort of 196 drug users
prescribed methadone maintenance by general practitioners.
Defossez et al, 2008 France Cross-sectional
study
HCV antibody-positive people who reported drug use as a presumed mode of infection
in cross-sectional studies of patients newly diagnosed with HCV in 1997, 2000 and
2003. (Total numbers of newly diagnosed patients were 69, 58 and 96 respectively.)
Hernandez et al, 2009 Spain Retrospective
cohort study
Four HCV-RNA positive PWID in a hospital-based setting.




174 HCV antibody-positive drug users engaged in drug treatment services in a primary
care environment.
Kristensen et al, 2009 Norway Prospective
cohort study
Heroin-dependent patients in medical rehabilitation.
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France, with five. Germany, Ireland, Spain and the United
Kingdom all had three studies. (One of the three German
studies also included study sites in Austria.)
The 25 studies included one randomised controlled
study [16], three cross-sectional studies [17-19], 11 retro-
spective cohort studies [20-30] and 10 prospective cohort
studies [31-40]. Ten of the studies took place at drug treat-
ment clinics, five at hepatitis clinics, and ten in other types
of settings.
Overall treatment uptake levels and sustained viral
response
Treatment uptake levels were assessed for this review
using three different metrics. Some studies reported
treatment uptake in terms of more than one metric.
The HCV antibody-positive treatment uptake level
reflects the number of study participants who received
treatment as a proportion of the number of study partici-
pants known to have antibodies for hepatitis C. Ten studies
[19,22,24,26,32,35,36,38-40] reported treatment uptake
in relation to HCV antibody-positive status (Table 2).
Among groups of study participants who were HCV anti-
body-positive, treatment uptake ranged from 3% to 64%
(median: 17%).
The HCV RNA-positive treatment uptake level reflects
the number of study participants who received treatment
as a proportion of the number of study participants
known to be hepatitis C RNA-positive. Twenty-one stu-
dies [16-18,20-34,37,38,40] yielded 22 datasets with infor-
mation about HCV RNA-positive treatment uptake levels
(Table 3). (One study, by Moussalli et al [17], included an
observational phase and an intervention phase that
enrolled two separate groups of study participants; for
the purpose of calculating treatment uptake levels in this
review, the information is regarded as though it repre-
sents two studies.) Treatment uptake for groups of hepa-
titis C RNA-positive study participants ranged from 0%
to 61% (median: 30%).
The treatment uptake level for patients who were HCV
RNA-positive and met other criteria reflects the number
of study participants who received treatment as a pro-
portion of the number of study participants who both
were RNA-positive for hepatitis C and also met other
requirements for treatment, e.g., requirements relating
to HCV genotype or to current drug or alcohol intake.
Six studies [19,24,32,38-40] reporting on such groups of
study participants documented treatment uptake levels
ranging from 24% to 76% (median, 55%) (Table 4).
Table 1 Characteristics of included studies (Continued)




277 HCV antibody-positive drug users referred to a hepatitis C treatment project for
drug users.
Perez-Alvarez et al, 2012 Spain Retrospective
cohort study
27 PWID within a cohort of 131 patients with acute HCV at 18 Spanish hospitals.
Perut et al, 2009 France Retrospective
cohort study
137 currently opioid-dependent people included in a cohort of HCV-RNA positive
inpatients or outpatients at a Paris hospital.




Study of HIV/HCV co-infected patients in 14 specialised clinical centres included 637
people who reported injecting drug use as HCV transmission route.
Table 2 Treatment uptake as defined by percentage of hepatitis C antibody-positive study participants who received
treatment
Author, year % treated (# treated/# of treatment candidates) SVR (%) (# with sustained viral response/# treated)
Cournot et al, 2004 36% (81/225) Intent-to-treat: 26% (26/99)1
Crespo et al, 2001 64% (268/416) NA
Cullen et al, 2007 3% (3/104) NA
Defossez et al, 2008 16% (13/84)2 NA
Grando-Lemaire et al, 2002 12% (27/225) Intent-to-treat: 19% (5/27)
As-treated: 33% (5/15)
Jack et al, 2009 17% (30/174) Intent-to-treat: 62% (13/21)
As-treated: 77% (13/17)
Jowett et al, 2000 20% (50/253) Intent-to-treat: 36% (18/50)
Kristensen et al, 2009 4% (6/160) NA
Lindenburg et al, 2011 21% (58/277) Intent-to-treat: 65% (37/57)
As-treated: 77% (37/48)
Schulte et al, 2010 9% (26/301) Intent-to-treat: 69% (18/26)
As-treated: 86% (18/21)
1. Calculated according to the number of treatment outcomes (N=99) rather than the number of patients (N=81)
2. Study population represents study cohorts from a cross-sectional survey carried out at three time points: 1997 (N=35), 2000 (N=19) and 2003 (N=30).
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Table 3 Treatment uptake as defined by percentage of hepatitis C RNA-positive study participants who received
treatment
Author, year % treated (# treated/# of treatment candidates) SVR (%) (# with sustained viral response/# treated)
Backmund et al, 2001 50% (50/100) Intent-to-treat: 36% (18/50)
Broers et al, 2005 61% (11/18) Intent-to-treat: 56% (6/11)
As-treated: 100% (3/3)
Cournot et al, 2004 54% (81/151) Intent-to-treat: 26% (26/99)1
Cullen et al, 2007 10% (3/29) NA
Ebner et al, 2009 23% (17/75) Intent-to-treat: 88% (15/17)
As-treated: 88% (15/17)
Gazdag et al, 2010 47% (39/83) NA
Grando-Lemaire et al, 2002 28% (27/97) Intent-to-treat: 19% (5/27)
As-treated: 33% (5/15)
Guadagnino et al, 2007 31% (53/169) Intent-to-treat: 55% (29/53)
As-treated: 85% (29/34)
Hernandez et al, 2009 0% (0/4) NA
Jack et al, 2009 25% (30/118) Intent-to-treat: 62% (13/21)
As-treated: 77% (13/17)
Jowett et al, 2000 29% (50/172) Intent-to-treat: 36% (18/50)
Kieran et al, 2011 21% (67/327) Intent-to-treat: 43% (29/67)
Lindenburg et al, 2011 30% (58/196) Intent-to-treat: 65% (37/57)
As-treated: 77% (37/48)
McCormick et al, 2008 46% (6/13) Intent-to-treat: 83% (5/6)
As-treated: 83% (5/6)
Moussalli et al, 20102 2% (2/113) NA
Moussalli et al, 20102 38% (85/224) Intent-to-treat: 43% (37/85)
Perez-Alvarez et al, 2012 56% (15/27) NA
Perut et al, 2009 9% (12/137) NA
Reiberger et al, 2011 32% (201/637) NA
van der Veen, 2009 48% (35/73) NA
Wilkinson et al, 2008 14% (63/441) As-treated: 51% (25/49)3
Witteck et al, 2011 15% (29/193) Intent-to-treat: 52% (13/25)
1. Calculated according to the number of treatment outcomes (N=99) rather than the number of patients who initiated therapy (N=81)
2. The study by Moussalli et al includes separate study populations for an observational phase (N=113) and an intervention phase (N=224), and those study
populations are represented by two separate records in this table.
3. Calculated according to the number of treatment outcomes (N=49) rather than the number of patients who completed therapy (N=58)
Table 4 Treatment uptake as defined by percentage of eligible study participants who received treatment, with
eligibility for treatment determined by hepatitis C RNA-positive status and other criteria
Author, year % treated (# treated/# of treatment candidates) SVR (%) (# with sustained viral response/# treated)
Defossez et al, 2008 24% (13/55)1 NA
Grando-Lemaire et al, 2002 58% (27/47) Intent-to-treat: 19% (5/27)
As-treated: 33% (5/15)
Jack et al, 2009 70% (30/43) Intent-to-treat: 62% (13/21)
As-treated: 77% (13/17)
Jowett et al, 2000 50% (50/100) Intent-to-treat: 36% (18/50)
Kristensen et al, 2009 33% (6/9) NA
Lindenburg et al, 2011 76% (58/76) Intent-to-treat: 65% (37/57)
As-treated: 77% (37/48)
1. Study population represents study cohorts from a cross-sectional survey carried out at three time points: 1997 (N=26), 2000 (N=11) and 2003 (N=18).
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Data on sustained viral response (SVR) were available
for 15 of the 25 studies [16-18,21,22,24,25,31-35,37,38,40]
included in the review, with some studies reporting intent-
to-treat outcomes, some studies reporting as-treated out-
comes, and some studies reporting both (Tables 2, 3, 4).
For 14 studies with intent-to-treat data, the proportion of
treated study participants attaining a sustained viral
response ranged from 19% to 88% (median, 55%). For nine
studies with as-treated data, SVR levels ranged from 33%
to 100% (median, 80%).
Treatment uptake levels for key drug-using populations
For 11 studies [20,22-25,27,28,30,33,36,37] included in
the review, treatment uptake levels could be calculated
specifically for current and former PWID (Table 5).
(Other studies had study populations that included
non-injecting drug users.) In these studies, the HCV
antibody-positive treatment uptake level ranged from
20% to 64% (three studies, median 39%). The HCV
RNA-positive treatment uptake level ranged from 0%
to 57% (nine studies, median 32%). For two studies
reporting treatment uptake in terms of RNA-positive
status plus additional criteria, treatment uptake levels
were 50% and 71%.
Five of the PWID-specific studies reported intent-to-
treat SVR levels [22,24,25,33,37]; these ranged from 22%
to 56% (median, 43%) (Table 5). Two reported as-treated
SVR levels [33,37]; these were 85% and 100%.
For four studies included in the review [18,22,26,35],
treatment uptake levels could be calculated specifically
for people receiving opioid substitution therapy (OST)
(Table 6). (Some other study populations included both
people receiving OST and people not receiving OST.) In
these studies, the HCV antibody-positive treatment
uptake level ranged from 3% to 31% (three studies, med-
ian 9%). The HCV RNA-positive treatment uptake level
ranged from 10% to 47% (three studies, median 15%).
For one study reporting treatment uptake in terms of
RNA-positive status plus additional criteria, the treat-
ment uptake level was 72%.
Three of the OST-specific studies reported intent-to-
treat SVR levels [18,22,35]; these ranged from 36% to
69% (median, 52%) (Table 6). One reported an as-treated
SVR level [35]; this was 86%.
Among the 25 studies, only one provided treatment
uptake data specifically for current drug users. Cournot
et al [22] reported on a study population of current and
former PWID, including people receiving OST. Disag-
gregated data for current drug users indicated an HCV
antibody-positive treatment uptake level of 39% (16/41).
The HCV RNA-positive treatment uptake level for the
same study subset was 50% (16/32). Among current
drug users who were HCV RNA-positive and met addi-
tional criteria, treatment uptake was 55% (16/29). The
intent-to-treat SVR for current drug users in the study
by Cournot et al was 16% (data not shown).
Table 5 Treatment uptake in study cohorts of people who inject drugs (current and former)
Author, year % treated (# treated/# of treatment candidates SVR (%) (# with sustained viral response/# treated)
Broers et al, 2005 61% of RNA+ (11/18) Intent-to-treat: 56% (6/11)
As-treated: 100% (3/3)
Cournot et al, 2004 39% of antibody+ (58/150) Intent-to-treat: 22% (15/68)1
57% of RNA+ (58/102)
71% of other (58/82)
Crespo et al, 2001 64% of antibody+ (268/416) NA
Gazdag et al, 2010 47% of RNA+ (39/83) NA
Guadagnino et al, 2007 31% of RNA+ (53/169) Intent-to-treat: 55% (29/53)
As-treated: 85% (29/34)
Hernandez et al, 2009 0% of RNA+ (0/4) NA
Jowett et al, 2000 20% of antibody+ (50/253) Intent-to-treat: 36% (18/50)
29% of RNA+ (50/172)
50% of other (50/100)
Kieran et al, 2011 21% of RNA+ (67/327) Intent-to-treat: 43% (29/67)
Perez-Alvarez et al, 2012 56% of RNA+ (15/27) NA
Reiberger et al, 2011 32% of RNA+ (201/637) NA
van der Veen, 2009 48% of RNA+ (35/73) NA
Antibody+ = study participants who are hepatitis C antibody-positive
RNA+ = study participants who are hepatitis C RNA-positive
Other = study participants who are hepatitis C RNA-positive and meet additional treatment criteria
1. Calculated according to the number of treatment outcomes (N=68) rather than the number of patients who initiated therapy (N=58)
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Age and sex of treatment initiators
The mean age of HCV treatment initiators was available
for eight studies; it ranged from 29 to 48 (mean, 34). In
the nine studies that disaggregated the sex of treatment
initiators, the percentage of female treatment initiators
ranged from 9% to 85% (mean, 26%) (data not shown).
Discussion
This systematic review found that hepatitis C treatment
uptake is relatively low among drug users in several coun-
tries in the WHO European Region, and also that consid-
erable knowledge gaps exist regarding treatment uptake
levels in drug users generally and people who inject drugs
specifically. There was large variability in treatment uptake
levels, with six studies reporting treatment uptake levels
below 20% in HCV RNA-positive drug-using study popu-
lations, while four reported treatment uptake levels of 50%
or higher. However, the median treatment uptake level
was alarmingly low, at 30%.
The apparent failure of many European health systems
to engage a key population that needs HCV treatment is
even more striking in light of the health care resources
that appear to be available. For example, the governments
of France, Ireland, Spain and the United Kingdom all have
reported that the HCV drugs interferon alpha, pegylated
interferon, ribavirin, boceprevir and telaprevir are either
government-subsidised or are on the national essential
medicines lists in those countries [41]. Yet 14 studies from
those countries are among the studies demonstrating low
treatment uptake among drug users. This may partially
reflect recent findings from a survey of civil society organi-
sations, which reports low capacity and extremely limited
resources among non-governmental organisations addres-
sing hepatitis [42].
The majority of studies identified by our review included
both people who inject drugs and non-injecting drug users
in their study populations without providing disaggregated
data for these two subgroups. Interestingly, the 11 articles
with data specifically for people who inject drugs showed a
median treatment uptake level of 32% among HCV RNA-
positive PWID – comparable to the median treatment
uptake level for the full set of studies. Nonetheless, the
fact remains that policy-makers, programme managers
and researchers currently possess extremely limited infor-
mation about the extent to which hepatitis C treatment is
reaching the population whose primary risk behaviour –
injecting drug use – is the main driver of the hepatitis C
epidemic in Europe.
The current situation is likely a legacy of the medical
community’s initial outlook on hepatitis C treatment for
PWID, which was to not treat current or even past injec-
tors. Although treatment adherence, efficacy and safety
have been shown to be quite comparable between PWID
and those with no history of drug use, several interna-
tional and national treatment guidelines in the 1990s and
at the beginning of the new millennium excluded PWID
from being treated for hepatitis C [8,9,43]. In a revision
of its guidelines in 2011, the European Association for
the Study of the Liver (EASL) made the important deci-
sion to advise instituting antiviral therapy in PWID on
stable maintenance substitution treatment after careful
individual evaluation by an interdisciplinary team of
hepatologists and addiction specialists.As for current
drug injectors, an individualised approach after evalua-
tion and close monitoring by an experienced multidisci-
plinary team were recommended [44].
EASL published a new revision of its guidelines in
2013, and this document reflects the continuing evolu-
tion of medical perspectives on the treatment of hepatitis
C in drug users and patients on stable maintenance sub-
stitution therapy [45]. According to the guidelines, HCV
treatment should be considered for PWID on a case-by-
case basis, provided they wish to receive it and are willing
and able to maintain regular follow-up visits to a multi-
disciplinary medical service as well as obtain a pre-treat-
ment assessment. The assessment should take into
Table 6 Treatment uptake in study cohorts receiving opioid substitution therapy
Author, year % treated (# treated/# of treatment candidates SVR (%) (# with sustained viral response/# treated)
Cournot et al, 2004 31% of antibody+ (23/75) Intent-to-treat: 36% (11/31)1
47% of RNA+ (23/49)
72% of other (23/32)
Cullen et al, 2007 3% of antibody+ (3/104) NA
10% of RNA+ (3/29)
Schulte et al, 20102 9% of antibody+ (26/301) Intent-to-treat: 69% (18/26)
As-treated: 86% (18/21)
Witteck et al, 20112 15% of RNA+ (29/193) Intent-to-treat: 52% (13/25)
Antibody+ = study participants who are hepatitis C antibody-positive
RNA+ = study participants who are hepatitis C RNA-positive
Other = study participants who are hepatitis C RNA-positive and meet additional treatment criteria
1. Calculated according to the number of treatment outcomes (N=31) rather than the number of patients who initiated therapy (N=23)
2. Study cohort received heroin maintenance therapy
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account several factors that may influence adherence to
therapy and the likelihood of achieving a sustained viral
response, such as ongoing drug use, alcohol consump-
tion, psychiatric disorders, housing, education, employ-
ment, and social and financial status. Accordingly, closer
monitoring and more intensive multidisciplinary support
are needed in certain cases.
The problem is that there appears to be a vast gulf
between evidence-based best practice and the decision-
making of physicians who encounter HCV RNA-positive
drug users seeking care in their clinics. Research indi-
cates that some physicians are reluctant to provide
hepatitis C treatment to people who inject drugs, espe-
cially those whose drug use is ongoing. For example, a
study of private practitioners in Switzerland found that
a major reason for non-treatment was intravenous drug
use [46].
Even in a research context, where one might hope that
treatment criteria for participant-patients are determined
in keeping with the established evidence base, current
illicit drug use seems to be a legitimate reason for not
providing HCV treatment. For example, a 2009 article
included in our review described a study that sought “to
assess the feasibility and efficacy of antiviral therapy in
opioid-dependent patients” by providing one of two HCV
treatment regimens to patients at an Austrian addiction
clinic. However, participation in the study required meet-
ing one or both of two conditions at the time of enrol-
ment: being in drug maintenance therapy, and abstaining
from illicit drugs for at least six months [16].
Other factors commonly associated with injecting drug
use may result in the patient’s drug use indirectly creating
barriers to HCV treatment. For example, a 2011 article
included in the review describes a prospective cohort
study in which Dutch drug users were referred to a multi-
disciplinary hepatitis C treatment unit. Current drug and
alcohol use were not considered treatment exclusion cri-
teria. However, in order to be eligible for treatment, drug
users “were required to have stable housing and no acute
or uncared for juridical or financial impediments” [40].
Another study excluded hepatitis patients coinfected with
HIV [31]. While in the context of a study there may be
legitimate scientific reasons for excluding certain cate-
gories of would-be study participants, in order to avoid
potential confounding of the results, these examples do
illustrate some of the barriers PWID face in being treated
for their life-threatening condition.
Several studies have shown that treatment of PWID with
pegylated interferon alpha plus ribavirin has resulted in
sustained viral response levels of 54 to 56% [8,9,47] con-
firming that HCV-infected PWID can be successfully trea-
ted. There are some independent factors associated with
lower SVR in this group of patients, such as untreated
depression, poor socialization and ongoing drug use
during HCV treatment [48,49]. On the other hand, PWID
in many cases present baseline characteristics shown to be
associated with sustained viral response, such as young
age and mild liver disease [50]. The mean age in the stu-
dies included in this review ranged from 29 to 48, with an
aggregated mean of 34.
It has also been reported that a large obstacle to HCV
treatment and care for PWID is related to access to care,
described as a lack of treatment settings that are suitable
for this vulnerable group [12]. Various models for HCV
treatment delivery were employed in the articles included
in our review. The 2013 EASL guidelines call for a multi-
disciplinary approach regarding the treatment of HCV
infection in PWID including hepatologists and addiction
specialists, possibly combining them with other specialists.
Therapy can be delivered at community-based clinics, sub-
stance use treatment clinics or specialised clinics for the
treatment of viral hepatitis. Other options exist as well,
such as integrating treatment into primary, secondary or
tertiary care, as well as integrating interventions such as
directly observed therapy and peer treatment support [5].
The best way to reach the maximum number of infected
PWID is to offer the range of various local settings and
enable close ongoing collaboration of all involved health
professionals [5]. It is now time to further rethink treat-
ment and models of care for PWID.
Treatment not only has the likelihood of curing an indi-
vidual’s HCV infection, but as in the field of HIV/AIDS,
treatment as prevention is increasingly recognised [51].
Mathematical models predict that the transmission rate is
reduced when treatment uptake is increased [52-54].
Hence the apparent widespread failure to engage many
PWID who have hepatitis C in treatment represents not
only missed opportunities to avert potential suffering and
death from liver diseases on an individual level, but also
missed opportunities to slow an epidemic of major public
health significance.
Limitations
This literature review has several limitations which may
affect the findings. The review primarily contains studies
retrieved through PUBMED and EMBASE, which means
that the data are subject to publication bias. Drawing on
the protocol and methods from a previously published
study [15] these problems have been minimised by includ-
ing missed studies, including studies reported in other lan-
guages, provided by a network of drug and infectious
disease experts in the European Union. Even with this
additional component of the literature search, the 25 arti-
cles that met review criteria represent only 12 of the
European Region’s 53 Member States. Furthermore, esti-
mates of treatment entry are higher than in that of a
recent previous study [15] as there, estimates were only
presented for non-intervention (i.e. observational) studies
performed in non-clinical settings, whereas in this analysis
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we included all data available, noting the fact that esti-
mates are partly based on selected populations. The data
in our study are thus not directly comparable to the esti-
mates of the previous study, which as its main finding
found that overall a lower median (9.5%) of PWID who
were diagnosed with HCV among six observational and
non-clinical studies had received treatment. Further study
including meta-analysis is needed to better understand the
biases and generalisability of estimates of treatment access.
Large differences in treatment uptake were observed
across the studies included in this review, but since there
were major variations in study design and methodology, it
is possible that treatment uptake findings may reflect
these differences rather than real differences in treatment
uptake within and across countries. The following impor-
tant potential biases may have further influenced the
review findings. The included studies were largely under-
taken in various types of health care settings, and the
drug-using populations served in those settings may not
be representative of all people who use drugs. In a number
of studies, treatment delivery models were designed with
the goal of attracting and retaining people who use drugs,
for example by making treatment available at opioid sub-
stitution therapy clinics. In light of these considerations, it
can be expected that the percentages of people initiating
treatment would be higher than the percentage of drug
users who are actually initiating treatment in the popula-
tion at large.
A number of articles were excluded from this review
because of methodological shortcomings. Some reported
the number of drug users initiating HCV treatment but
did not report the total number of drug users who were
treatment candidates, making it impossible to determine
the proportion of treatment initiators (referred to in this
article as the treatment uptake level) [55-59]. Other arti-
cles needed to be excluded because they failed to explain
how treatment candidates were defined, i.e., it was not
clear if patients were considered treatment candidates on
the basis of their HCV antibody status, HCV-RNA status
or other criteria. Finally, although not part of the exclusion
criteria, most studies do not mention whether or not
patients were treatment naïve or if previous treatment
regimens had been discontinued due to, for example,
intolerance/side-effects or failure.
Conclusions
The availability of hepatitis C treatment data for drug-
using populations varies greatly across the WHO Eur-
opean Region. To the extent that treatment uptake
levels can be measured, it appears that major differences
exist in the proportions of drug users who undergo
hepatitis C treatment in different research settings.
However, the overall finding of this review suggests to is
that large proportions of people who use drugs, includ-
ing those who inject drugs, do not enter the treatment
pathway and do not receive treatment for their hepatitis
C infection.
This observation, coupled with evidence showing that
some physicians consider illicit drug use, HIV coinfection
and/or related social issues to be counter-indications for
hepatitis C treatment, leads us to suggest that a promis-
ing strategy for improving the situation is working to
increase knowledge and reduce misconceptions among
physicians, who play a pivotal role in encouraging or dis-
couraging the initiation of treatment in drug users. There
is furthermore great potential to build on integrated
health care models, both governmental and nongovern-
mental, that have demonstrated some success in provid-
ing drug users with the medical and social support
services that they need in order to optimise their chances
of benefitting from hepatitis C treatment. All such efforts
must be situated within stronger national efforts to
develop HCV treatment policies, strengthen service orga-
nisations and ultimately scale up HCV treatment for
PWID. In the research realm, future studies should
ensure the inclusion of clear criteria to determine if treat-
ment for HCV is needed and should report the indica-
tions for starting treatment. This, at a minimum, would
include HCV-RNA status, which a number of the
excluded articles for this review failed to report.
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